Show simple item record

AuthorCyprian, Farhan S
AuthorAkhtar, Saghir
AuthorGatalica, Zoran
AuthorVranic, Semir
Available date2019-03-28T10:09:22Z
Publication Date2019-03-01
Publication NameBosnian Journal of Basic Medical Science
Identifierhttp://dx.doi.org/10.17305/bjbms.2019.4204
CitationFarhan S. Cyprian, et al. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer. Bosnian Journal of Basic Medical Science. 2019
ISSN1512-8601
URIhttp://hdl.handle.net/10576/11458
AbstractThe treatment of several solid and hematologic malignancies with immune checkpoint inhibitors (against PD-1/PD-L1) has dramatically changed the cancer treatment paradigm. However, no checkpoint inhibitors were previously approved for the treatment of triple-negative breast cancer (TNBC), a difficult-to-treat disease with a high unmet therapeutic need. Based on IMpassion130 clinical trial (NCT02425891), FDA has recently granted an accelerated approval for atezolizumab (TECENTRIQ®), a monoclonal antibody drug targeting PD-L1, plus chemotherapy (Abraxane; nab®-Paclitaxel) for the treatment of adults with PD-L1-positive, unresectable, locally advanced or metastatic TNBC. FDA has also approved the Ventana diagnostic antibody SP142 as a companion test for selecting TNBC patients for treatment with atezolizumab. In the present review, we briefly discuss the importance of this breakthrough as the first cancer immunotherapy regimen to be approved for the management of breast cancer.
Languageen
PublisherAssociation of Basic Medical Sciences of Federation of Bosnia and Herzegovina
Subjectbreast cancer
immunotherapy
PD-L1
triple-negative breast cancer
immune checkpoint inhibitors
predictive biomarkers
TitleTargeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
TypeArticle Review
ESSN1840-4812
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record